News Archives - BioAegis Therapeutics https://www.bioaegistherapeutics.com/category/news/ The Power of Innate Immunity Tue, 21 Apr 2026 13:13:14 +0000 en hourly 1 https://wordpress.org/?v=6.9.4 https://www.bioaegistherapeutics.com/wp-content/uploads/2020/02/cropped-BioAegis-Favicon500-32x32.webp News Archives - BioAegis Therapeutics https://www.bioaegistherapeutics.com/category/news/ 32 32 April 21, 2026: BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease https://www.bioaegistherapeutics.com/news/april-21-2025-bioaegis-therapeutics-announces-collaboration-with-prenosis-to-advance-ai-driven-precision-medicine-in-inflammatory-disease/?utm_source=rss&utm_medium=rss&utm_campaign=april-21-2025-bioaegis-therapeutics-announces-collaboration-with-prenosis-to-advance-ai-driven-precision-medicine-in-inflammatory-disease https://www.bioaegistherapeutics.com/news/april-21-2025-bioaegis-therapeutics-announces-collaboration-with-prenosis-to-advance-ai-driven-precision-medicine-in-inflammatory-disease/#respond Tue, 21 Apr 2026 13:09:17 +0000 https://www.bioaegistherapeutics.com/?p=5904 Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a strategic collaboration with Prenosis®, a leader in […]

The post April 21, 2026: BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease appeared first on BioAegis Therapeutics.

]]> https://www.bioaegistherapeutics.com/news/april-21-2025-bioaegis-therapeutics-announces-collaboration-with-prenosis-to-advance-ai-driven-precision-medicine-in-inflammatory-disease/feed/ 0 August 20, 2025: BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS) https://www.bioaegistherapeutics.com/news/august-20-2025-bioaegis-therapeutics-awarded-second-fda-fast-track-designation-for-recombinant-human-gelsolin-to-treat-inflammasome-driven-decompression-sickness-dcs/?utm_source=rss&utm_medium=rss&utm_campaign=august-20-2025-bioaegis-therapeutics-awarded-second-fda-fast-track-designation-for-recombinant-human-gelsolin-to-treat-inflammasome-driven-decompression-sickness-dcs Wed, 20 Aug 2025 15:35:12 +0000 https://www.bioaegistherapeutics.com/?p=4707 Fast Track status accelerates regulatory pathway for BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Second Fast Track designation in recent months highlights broad potential of rhu-pGSN across multiple diverse inflammation-driven conditions. NORTH BRUNSWICK, N.J., August 20, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of […]

The post August 20, 2025: BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS) appeared first on BioAegis Therapeutics.

]]> June 17, 2025: BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/june-17-2025-bioaegis-therapeutics-receives-fda-fast-track-designation-for-lead-product-recombinant-human-gelsolin-for-the-treatment-of-acute-respiratory-distress-syndrome-ards/?utm_source=rss&utm_medium=rss&utm_campaign=june-17-2025-bioaegis-therapeutics-receives-fda-fast-track-designation-for-lead-product-recombinant-human-gelsolin-for-the-treatment-of-acute-respiratory-distress-syndrome-ards Tue, 17 Jun 2025 14:24:30 +0000 https://www.bioaegistherapeutics.com/?p=4665 Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.  Global Phase 2b clinical trial underway evaluating rhu-pGSN for the treatment of moderate to severe ARDS.  NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech […]

The post June 17, 2025: BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]> June 10, 2025: BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS) https://www.bioaegistherapeutics.com/news/june-10-2025-bioaegis-therapeutics-announces-us-navy-contract-to-support-phase-2-study-of-recombinant-human-gelsolin-for-inflammasome-driven-decompression-sickness-dcs/?utm_source=rss&utm_medium=rss&utm_campaign=june-10-2025-bioaegis-therapeutics-announces-us-navy-contract-to-support-phase-2-study-of-recombinant-human-gelsolin-for-inflammasome-driven-decompression-sickness-dcs Tue, 10 Jun 2025 18:25:06 +0000 https://www.bioaegistherapeutics.com/?p=4653 Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of  inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers. NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory […]

The post June 10, 2025: BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS) appeared first on BioAegis Therapeutics.

]]> May 6, 2025: BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/may-6-2025-bioaegis-therapeutics-announces-site-activation-and-patient-recruitment-underway-in-13-countries-in-phase-2b-clinical-trial-of-gelsolin-an-immune-regulator-for-the-treatment-of-acute-re/?utm_source=rss&utm_medium=rss&utm_campaign=may-6-2025-bioaegis-therapeutics-announces-site-activation-and-patient-recruitment-underway-in-13-countries-in-phase-2b-clinical-trial-of-gelsolin-an-immune-regulator-for-the-treatment-of-acute-re Tue, 06 May 2025 01:55:20 +0000 https://www.bioaegistherapeutics.com/?p=4621 600-patient study to assess efficacy of rhu-pGSN,  an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens.  Results from this landmark study expected to inform therapeutic strategies beyond ARDS, positioning rhu-pGSN as a promising intervention across a spectrum of acute and chronic inflammatory diseases.  NORTH BRUNSWICK, N.J., May 6, 2025 […]

The post May 6, 2025: BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]> March 18, 2025: BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences https://www.bioaegistherapeutics.com/news/march-18-2025-bioaegis-therapeutics-to-highlight-lead-product-gelsolins-critical-role-in-immune-function-at-upcoming-conferences/?utm_source=rss&utm_medium=rss&utm_campaign=march-18-2025-bioaegis-therapeutics-to-highlight-lead-product-gelsolins-critical-role-in-immune-function-at-upcoming-conferences Tue, 18 Mar 2025 18:36:40 +0000 https://www.bioaegistherapeutics.com/?p=4531 Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025.  COO Valerie Ceva will present at MedInvest Biotech & Pharma Investor Conference in NYC on March 27, 2025.  NORTH BRUNSWICK, N.J., March 18, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, […]

The post March 18, 2025: BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences appeared first on BioAegis Therapeutics.

]]> October 17, 2024: BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/october-17-2024-bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune-regulator-for-the-treatment-of-acute-respiratory-distress-syndrome-ards/?utm_source=rss&utm_medium=rss&utm_campaign=october-17-2024-bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune-regulator-for-the-treatment-of-acute-respiratory-distress-syndrome-ards Thu, 17 Oct 2024 12:05:20 +0000 https://www.bioaegistherapeutics.com/?p=4387 Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.  Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Endogenous levels plummet in ARDS, correlating with disease severity.  NORTH BRUNSWICK, N.J., October 17, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, […]

The post October 17, 2024: BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]> September 12, 2024: BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC https://www.bioaegistherapeutics.com/news/september-12-2024-bioaegis-therapeutics-to-present-at-upcoming-medinvest-biotech-amp-pharma-investor-conference-in-nyc/?utm_source=rss&utm_medium=rss&utm_campaign=september-12-2024-bioaegis-therapeutics-to-present-at-upcoming-medinvest-biotech-amp-pharma-investor-conference-in-nyc Thu, 12 Sep 2024 21:12:12 +0000 https://www.bioaegistherapeutics.com/?p=4339 NORTH BRUNSWICK, N.J., September 12, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its Co-founder, Steve Cordovano, will present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City on September 18 and 19. The presentation, “Conquering Diseases Driven […]

The post September 12, 2024: BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC appeared first on BioAegis Therapeutics.

]]> February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/february-27-2024-bioaegis-therapeutics-unveils-upcoming-clinical-study-of-gelsolin-an-immune-regulator-as-a-treatment-for-patients-with-acute-respiratory-distress-syndrome-ards/?utm_source=rss&utm_medium=rss&utm_campaign=february-27-2024-bioaegis-therapeutics-unveils-upcoming-clinical-study-of-gelsolin-an-immune-regulator-as-a-treatment-for-patients-with-acute-respiratory-distress-syndrome-ards Tue, 27 Feb 2024 21:28:57 +0000 https://www.bioaegistherapeutics.com/?p=4000 Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., February 27, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study […]

The post February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]> October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/october-16-2023-bioaegis-therapeutics-awarded-20-million-barda-drive-contract-to-advance-gelsolin-an-immune-regulator-as-a-treatment-for-patients-with-acute-respiratory-distress-syndrome-ards/?utm_source=rss&utm_medium=rss&utm_campaign=october-16-2023-bioaegis-therapeutics-awarded-20-million-barda-drive-contract-to-advance-gelsolin-an-immune-regulator-as-a-treatment-for-patients-with-acute-respiratory-distress-syndrome-ards Mon, 16 Oct 2023 18:47:45 +0000 https://www.bioaegistherapeutics.com/?p=3902 Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., October 16, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership […]

The post October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]>